Patents by Inventor Karl-Uwe Petersen

Karl-Uwe Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200253983
    Abstract: The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.
    Type: Application
    Filed: March 24, 2020
    Publication date: August 13, 2020
    Inventors: Karl-Uwe Petersen, Derek Jo Sakata, Thomas Stohr, John Graham, Brett Coopers, Tatjana Bevans, Christopher Reilly
  • Publication number: 20190175613
    Abstract: The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.
    Type: Application
    Filed: April 18, 2017
    Publication date: June 13, 2019
    Applicant: Paion UK Limited
    Inventors: Karl-Uwe Petersen, Derek Jo Sakata, Thomas Stöhr, John Graham, Brett Cooper, Tatjana Bevans, Christopher Reilly
  • Publication number: 20180371082
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 27, 2018
    Inventors: Fabian DOCAGNE, Richard MACREZ, Denis VIVIEN, Karl-Uwe PETERSEN
  • Patent number: 10072077
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: September 11, 2018
    Assignees: PAION DEUTSCHLAND, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE CAEN NORMANDIE
    Inventors: Fabian Docagne, Richard Macrez, Denis Vivien, Karl-Uwe Petersen
  • Publication number: 20160115230
    Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-as-partate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
    Type: Application
    Filed: May 21, 2014
    Publication date: April 28, 2016
    Inventors: Fabian DOCAGNE, Richard MACREZ, Denis VIVIEN, Karl-Uwe PETERSEN
  • Publication number: 20140256640
    Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
    Type: Application
    Filed: September 13, 2013
    Publication date: September 11, 2014
    Applicant: Paion Deutschland GmbH
    Inventors: Karl-Uwe Petersen, Michael Ernest Nesheim, Jonathan Herbert Foley
  • Publication number: 20130058939
    Abstract: The invention relates to a protein or peptide consisting of a kringle protein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody.
    Type: Application
    Filed: February 29, 2012
    Publication date: March 7, 2013
    Applicants: INSERM, PAION DEUTSCHLAND GMBH
    Inventors: Denis Vivien, Carine Ali, Richard Macrez, Karl-Uwe Petersen
  • Publication number: 20120270789
    Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
    Type: Application
    Filed: June 12, 2009
    Publication date: October 25, 2012
    Applicant: PAION Deutschland GmbH
    Inventors: Karl-Uwe Petersen, Michael Ernest Nesheim, Daniel Nesheim, Jonathan Herbert Foley
  • Publication number: 20110144024
    Abstract: The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.
    Type: Application
    Filed: September 23, 2008
    Publication date: June 16, 2011
    Applicant: PAION Deutschland GmbH
    Inventors: Karl-Uwe Petersen, Martin Hauer-Jensen